Goldman Sachs’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$285M Buy
11,412,008
+1,431,388
+14% +$37.3M 0.02% 570
2026
Q2
$312M Buy
9,980,620
+4,904,228
+97% +$121M 0.03% 578
2026
Q1
$106M Buy
5,076,392
+133,978
+3% +$1.86M 0.01% 987
2025
Q4
$43.8M Buy
4,942,414
+3,432,939
+227% +$29.6M 0.01% 1617
2025
Q3
$12.7M Buy
1,509,475
+1,401,296
+1,295% +$9.48M ﹤0.01% 2735
2025
Q2
$554K Sell
108,179
-64,254
-37% -$159K ﹤0.01% 5095
2025
Q1
$236K Sell
172,433
-314,455
-65% -$772K ﹤0.01% 5568
2024
Q4
$1.5M Sell
486,888
-56,609
-10% -$263K ﹤0.01% 4528
2024
Q3
$4.18M Sell
543,497
-71,421
-12% -$682K ﹤0.01% 3498
2024
Q2
$5.28M Buy
614,918
+1,216
+0.2% +$9.4K ﹤0.01% 3101
2024
Q1
$4.87M Buy
613,702
+164,487
+37% +$1.76M ﹤0.01% 3112
2023
Q4
$4.45M Buy
449,215
+334,355
+291% +$2.9M ﹤0.01% 3261
2023
Q3
$1.29M Buy
114,860
+24,293
+27% +$148K ﹤0.01% 4087
2023
Q2
$301K Buy
90,567
+9,408
+12% +$33.8K ﹤0.01% 5002
2023
Q1
$321K Buy
81,159
+11,125
+16% +$64.6K ﹤0.01% 5071
2022
Q4
$508K Sell
70,034
-204,552
-74% -$1.44M ﹤0.01% 4857
2022
Q3
$994K Buy
274,586
+194,191
+242% +$829K ﹤0.01% 4507
2022
Q2
$364K Sell
80,395
-21,391
-21% -$130K ﹤0.01% 5301
2022
Q1
$772K Buy
101,786
+19,180
+23% +$166K ﹤0.01% 5030
2021
Q4
$904K Buy
+82,606
New +$993K ﹤0.01% 4932

Other funds holding TNGX

Goldman Sachs's TNGX Position: Q3 2026 in Review

Goldman Sachs increased its Tango Therapeutics (TNGX) stake by 14% in Q3 2026, buying an estimated $37.3M and bringing the position to 11,412,008 shares worth $285M. The position accounts for 0.02% of the portfolio, ranked #570.

Goldman Sachs first reported a position in TNGX in Q4 2021 and has held it in 20 quarters since. The position peaked at $312M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Goldman Sachs held 11,412,008 shares of Tango Therapeutics worth $285M as of Q3 2026.
  • Goldman Sachs bought 1,431,388 Tango Therapeutics shares in Q3 2026, an estimated $37.3M.
  • Tango Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q3 2026, its #570 holding.
  • Goldman Sachs first reported a position in Tango Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Tango Therapeutics position peaked at $312M in Q2 2026.
  • 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.